CRISPR-mediated Genome Editing Restores Dystrophin Expression and Function in mdx Mice.

Duchenne muscular dystrophy (DMD) is a degenerative muscle disease caused by genetic mutations that lead to the disruption of dystrophin in muscle fibers. There is no curative treatment for this devastating disease. Clustered regularly interspaced short palindromic repeat/Cas9 (CRISPR/Cas9) has emerged as a powerful tool for genetic manipulation and potential therapy. Here we demonstrate that CRIPSR-mediated genome editing efficiently excised a 23-kb genomic region on the X-chromosome covering the mutant exon 23 in a mouse model of DMD, and restored dystrophin expression and the dystrophin-glycoprotein complex at the sarcolemma of skeletal muscles in live mdx mice. Electroporation-mediated transfection of the Cas9/gRNA constructs in the skeletal muscles of mdx mice normalized the calcium sparks in response to osmotic shock. Adenovirus-mediated transduction of Cas9/gRNA greatly reduced the Evans blue dye uptake of skeletal muscles at rest and after downhill treadmill running. This study provides proof evidence for permanent gene correction in DMD.

[1]  J. Stull,et al.  Neuronal nitric oxide synthase and dystrophin-deficient muscular dystrophy. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[2]  F. Gleason,et al.  Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA , 2014 .

[3]  E. Signori,et al.  Optimisation of electrotransfer of plasmid into skeletal muscle by pretreatment with hyaluronidase – increased expression with reduced muscle damage , 2001, Gene Therapy.

[4]  Hao Yin,et al.  Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype , 2014, Nature Biotechnology.

[5]  Jianjie Ma,et al.  Uncontrolled calcium sparks act as a dystrophic signal for mammalian skeletal muscle , 2005, Nature Cell Biology.

[6]  G. van Ommen,et al.  Theoretic applicability of antisense‐mediated exon skipping for Duchenne muscular dystrophy mutations , 2009, Human mutation.

[7]  James E. DiCarlo,et al.  RNA-Guided Human Genome Engineering via Cas9 , 2013, Science.

[8]  K. Campbell.  Three muscular dystrophies: Loss of cytoskeleton-extracellular matrix linkage , 1995, Cell.

[9]  Tetsushi Sakuma,et al.  Precise Correction of the Dystrophin Gene in Duchenne Muscular Dystrophy Patient Induced Pluripotent Stem Cells by TALEN and CRISPR-Cas9 , 2014, Stem cell reports.

[10]  M. Koenig,et al.  Complete cloning of the duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals , 1987, Cell.

[11]  K. Moore,et al.  X chromosome-linked muscular dystrophy (mdx) in the mouse. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[12]  K. Campbell,et al.  Molecular basis of muscular dystrophies , 2000, Muscle & nerve.

[13]  Hans Clevers,et al.  Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. , 2013, Cell stem cell.

[14]  A. Emery.  Population frequencies of inherited neuromuscular diseases—A world survey , 1991, Neuromuscular Disorders.

[15]  J. Hennessey,et al.  Evaluation of accuracy and precision of adenovirus absorptivity at 260 nm under conditions of complete DNA disruption. , 2002, Virology.

[16]  K. Campbell,et al.  Loss of sarcolemma nNOS in sarcoglycan‐deficient muscle , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  M. Brotto,et al.  Disrupted Membrane Structure and Intracellular Ca2+ Signaling in Adult Skeletal Muscle with Acute Knockdown of Bin1 , 2011, PloS one.

[18]  E. Olson,et al.  Prevention of muscular dystrophy in mice by CRISPR/Cas9–mediated editing of germline DNA , 2014, Science.

[19]  K. Davies,et al.  Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers , 2015, Nature Medicine.

[20]  K. Davies,et al.  Very mild muscular dystrophy associated with the deletion of 46% of dystrophin , 1990, Nature.

[21]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.

[22]  Wei Tang,et al.  Correction of a genetic disease in mouse via use of CRISPR-Cas9. , 2013, Cell stem cell.

[23]  H. Aihara,et al.  Gene transfer into muscle by electroporation in vivo. , 1998, Nature biotechnology.

[24]  Gregory Q. Wallace,et al.  Mechanisms of muscle degeneration, regeneration, and repair in the muscular dystrophies. , 2009, Annual review of physiology.

[25]  M. Grounds,et al.  Measurement of sub-membrane [Ca2+] in adult myofibers and cytosolic [Ca2+] in myotubes from normal and mdx mice using the Ca2+ indicator FFP-18. , 2006, Cell calcium.

[26]  William H. Majoros,et al.  Multiplex CRISPR/Cas9-Based Genome Editing for Correction of Dystrophin Mutations that Cause Duchenne Muscular Dystrophy , 2015, Nature Communications.

[27]  M. Grounds,et al.  Evans Blue Dye as an in vivo marker of myofibre damage: optimising parameters for detecting initial myofibre membrane permeability , 2002, Journal of anatomy.

[28]  Eric P. Hoffman,et al.  Dystrophin: The protein product of the duchenne muscular dystrophy locus , 1987, Cell.

[29]  Andrew P. Weir,et al.  Function and genetics of dystrophin and dystrophin-related proteins in muscle. , 2002, Physiological reviews.

[30]  G. van Ommen,et al.  Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications. , 2007, RNA.